These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 19887258)
1. [The pathologist and targeted therapies in oncology]. Bertheau P Ann Pathol; 2009 Nov; 29 Spec No 1():S69-70. PubMed ID: 19887258 [No Abstract] [Full Text] [Related]
2. [Therapeutic targeting in breast cancer]. Penault-Llorca F Ann Pathol; 2009 Nov; 29 Spec No 1():S71-3. PubMed ID: 19887259 [No Abstract] [Full Text] [Related]
3. [Molecular markers having a prognostic or therapeutic value in cancer]. Brousset P Ann Pathol; 2008 Nov; 28 Spec No 1(1):S69-70. PubMed ID: 18984307 [No Abstract] [Full Text] [Related]
4. Biomarker targets and novel therapeutics. Clouser M; Hess LM; Chambers SK Cancer Treat Res; 2009; 149():85-105. PubMed ID: 19763432 [No Abstract] [Full Text] [Related]
6. [Targeted therapies in soft-tissue and visceral sarcomas]. Emile JF Ann Pathol; 2009 Nov; 29 Spec No 1():S81-2. PubMed ID: 19887262 [No Abstract] [Full Text] [Related]
7. [Molecular diagnosis and therapy in oncology]. Baretton G; Grabbe S; Keilholz U; Sauter G Onkologie; 2011; 34 Suppl 2():5-9. PubMed ID: 21447986 [No Abstract] [Full Text] [Related]
8. [Responses to targeted therapies: lung cancer]. Brambilla E Ann Pathol; 2009 Nov; 29 Spec No 1():S77-80. PubMed ID: 19887261 [No Abstract] [Full Text] [Related]
9. The development of molecularly targeted anticancer therapies: an Eli Lilly and Company perspective. Perry WL; Weitzman A Clin Adv Hematol Oncol; 2005 Mar; 3(3):199-202, 237-8. PubMed ID: 16166991 [TBL] [Abstract][Full Text] [Related]
10. Targeted therapies: aiming for the bull's-eye. Gaguski ME ONS Connect; 2007 Jul; 22(7):8-12. PubMed ID: 17694778 [No Abstract] [Full Text] [Related]
12. Targeting survivin in cancer therapy: fulfilled promises and open questions. Pennati M; Folini M; Zaffaroni N Carcinogenesis; 2007 Jun; 28(6):1133-9. PubMed ID: 17341657 [TBL] [Abstract][Full Text] [Related]
13. Predictive biomarkers in the development of oncology drugs: a therapeutic industry perspective. Fine BM; Amler L Clin Pharmacol Ther; 2009 May; 85(5):535-8. PubMed ID: 19295504 [No Abstract] [Full Text] [Related]
14. Clinical trial design and end points for epidermal growth factor receptor-targeted therapies: implications for drug development and practice. Arteaga CL; Baselga J Clin Cancer Res; 2003 May; 9(5):1579-89. PubMed ID: 12738709 [No Abstract] [Full Text] [Related]
15. Clinical cancer research 2001: new agents and therapies. Verweij J; de Vries EG Drug Resist Updat; 2001 Aug; 4(4):217-23. PubMed ID: 11991676 [No Abstract] [Full Text] [Related]
16. Cells carry the clue for targeted treatment: a new horizon for cytopathology. Schmitt FC Cytopathology; 2007 Oct; 18(5):275-7. PubMed ID: 17883688 [No Abstract] [Full Text] [Related]
17. Telomerase as a diagnostic and therapeutic target for cancer. Doyle LA; Highsmith WE Expert Rev Anticancer Ther; 2002 Apr; 2(2):217-25. PubMed ID: 12113243 [TBL] [Abstract][Full Text] [Related]
18. Targeted therapies: a nursing perspective. Kay P Semin Oncol Nurs; 2006 Feb; 22(1 Suppl 1):1-4. PubMed ID: 16616280 [TBL] [Abstract][Full Text] [Related]